Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Return on Assets (2016 - 2025)

Historic Return on Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to 0.22%.

  • Cartesian Therapeutics' Return on Assets rose 3000.0% to 0.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.22%, marking a year-over-year increase of 3000.0%. This contributed to the annual value of 0.21% for FY2024, which is 7200.0% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Return on Assets stood at 0.22% for Q3 2025, which was up 3000.0% from 0.2% recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Return on Assets high stood at 0.15% for Q3 2022, and its period low was 1.18% during Q4 2023.
  • Over the past 5 years, Cartesian Therapeutics' median Return on Assets value was 0.2% (recorded in 2025), while the average stood at 0.24%.
  • In the last 5 years, Cartesian Therapeutics' Return on Assets tumbled by -13000bps in 2023 and then surged by 10900bps in 2024.
  • Cartesian Therapeutics' Return on Assets (Quarter) stood at 0.08% in 2021, then skyrocketed by 248bps to 0.12% in 2022, then plummeted by -1043bps to 1.18% in 2023, then soared by 93bps to 0.08% in 2024, then tumbled by -168bps to 0.22% in 2025.
  • Its Return on Assets stands at 0.22% for Q3 2025, versus 0.2% for Q2 2025 and 0.1% for Q1 2025.